In osteosarcoma, ACLY drives tumor growth and metastasis via the XIST/miR-655/ACLY axis, while miR-22 downregulates ACLY to inhibit lipogenesis, highlighting its potential as a therapeutic target (167, 168). The gene discussed is XIST; the disease is neoplasm.